Iv Administration Articles & Analysis
6 news found
The company designed its novel delivery method to potentially eliminate the toxicity and debilitating side effects that chemo agents can produce when delivered systemically through traditional IV or oral administration. Its first potential indication is pancreatic cancer, a particularly lethal disease that affects more than 53,000 Americans annually, where ...
SeValent is designed to enable intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for use in the home setting. ...
“These data reaffirm our commitment to developing TSC as an adjuvant to standard of care therapy for hypoxic solid tumors, for which we are discussing a novel clinical protocol design for our planned Phase 2 Hypoxic Tumor Trial with the US Food and Drug Administration. We expect to initiate this trial in the second half of ...
ByCervoMed
Upgrading Trastuzumab from IV to Subcutaneous (SubQ) administration may now be possible without expensive, high-volume hyaluronidase injections. Due to patients’ convenience of at-home administration and reduced number of hospital visits as well as the reduction in treatment costs, SubQ administration of biologics is of ...
Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology. ...
It is approved for treating colorectal and pancreatic cancer as well as for gastric cancer in Japan. Today, the administration of irinotecan is intravenous (IV) bolus infusions, typically as a high dose every third week. ...